Genocea Biosciences HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses In Vaccinated Subjects
7/22/2014 11:22:33 AM
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today presented data from a Phase 1/2a study of GEN-003, the Company’s investigational immunotherapy against HSV-2, demonstrating that the immunotherapy elicited T cell, IgG and neutralizing antibody responses that remained significantly above baseline for 12 months after treatment. The data were presented at the 39th Annual International Herpesvirus Workshop, being held July 19-23, 2014 in Kobe, Japan.
Help employers find you! Check out all the jobs and post your resume.
comments powered by